Lifeboat Foundation

Researchers with Stanford University have published a study revealing that physical aging is not a smooth process, but rather something that happens in what they describe as a ‘herky-jerky trajectory.’ Using blood tests to look at specific proteins, the researchers found that human aging involves three distinct turning points, the first starting in one’s mid-thirties.

In back-to-back papers in the December 4 Science Translational Medicine, scientists led by Daniela Kaufer, University of California, Berkeley, and Alon Friedman, Ben-Gurion University of the Negev, Beer-Sheva, Israel, report that age-related cracks in the blood-brain barrier allow an influx of serum protein albumin into the brain, where they activate TGFβ receptors, overexcite neuronal networks, and impair cognition. Breaches correlated with localized slowing of cortical activity in epilepsy, Alzheimer’s disease patients, and in mouse models of AD. Called paroxysmal slow-wave events, these activity changes correlated with cognitive impairment and interspersed with seizures in epilepsy patients.

Dmitry Kaminskiy speaks as though he were trying to unload everything he knows about the science and economics of longevity—from senolytics research that seeks to stop aging cells from spewing inflammatory proteins and other molecules to the trillion-dollar life extension industry that he and his colleagues are trying to foster—in one sitting.

At the heart of the discussion with Singularity Hub is the idea that artificial intelligence will be the engine that drives breakthroughs in how we approach healthcare and healthy aging—a concept with little traction even just five years ago.

“At that time, it was considered too futuristic that artificial intelligence and data science … might be more accurate compared to any hypothesis of human doctors,” said Kaminskiy, co-founder and managing partner at Deep Knowledge Ventures, an investment firm that is betting big on AI and longevity.

Rejuvenation Biotechnology: on track to be the biggest industry ever.

Dr Aubrey de Grey, CSO at the SENS Research Foundation speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Aubrey discusses Rejuvenation biotechnology and how it’s on track to become the biggest industry ever.

Continue reading “Dr Aubrey de Grey | Investing in the Age of Longevity 2019” »

One of the most vexing questions many of us face once we hit our 60s is: Where should we live as we get older? I’m not talking about those “Best Places to Live” rankings. I mean what kind of home, and type of community, would be most suitable. That’s why I was eager to hear what several gerontologists had to say in their session at last week’s Gerontological Society of America conference about how they decided where they’d live in later life.

What kind of home and community is most suitable? The answer isn’t always rational.

Gene therapies to reverse immunosenescence and atherosclerosis.

CEO of Repair Biotechnologies speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Reason discusses gene therapies to reverse immunosenescence and atherosclerosis.

Continue reading “Reason | Investing in the Age of Longevity 2019” »

Your space questions, answered.

New research in mice suggests that a leaky blood-brain barrier can accelerate brain aging, and that targeting inflammation can reverse some changes.

New post!

Having a faster rate of epigenetic aging, as measured by the epigenetic age metric, AgeAccelGrim, is associated with a significantly increased risk of death for all causes in a variety of cohorts, including the Framingham Heart Study (FHS), the Women’s Health Initiative (WHI) study, the InChianti study, the Jackson Heart Study (JHS), and collectively, when evaluated as a meta-analysis (Lu et al. 2019):

Continue reading “Epigenetic Aging: Can It Be Slowed With Diet?” »